Genovis was granted SEK 1 million in research support from VINNOVA

Genovis has been granted SEK 1 million in research support from VINNOVA (the
Swedish Agency for Innovation Systems) to explore a method for online process
control in conjunction with manufacturing of the biological drug, mAbCHECK. The
project, which is being carried out in collaboration with CapSenze, runs until
2016.
Pharmaceutical companies have a constant need to improve their ability to
understand their process parameters and the parameters that give rise to or
affect the properties of biological drugs*. The ultimate goal is to control the
process by analyzing the product at different times and adjusting process
parameters when necessary to achieve a safe and effective biological drug as the
end product.

“In addition to patient safety, the pharmaceutical industry is interested in
being able to produce high-quality drugs at the lowest cost possible and the
project specifically intends to offer this group a reliable and automatic method
that saves both time and money in the customer's optimization of production
processes,” says Sarah Fredriksson, CEO at Genovis

*Biological drugs are produced in “living” cells, a production system that is
far more complex than pure chemical synthesis of small molecules. The industry
has a strong incentive to find rapid and automatable solutions to analyze
antibodies – preferably one that is fully automated, without any manual
intervention.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00